small molecule

LYNAVOY

LINERIXIBAT

Loss of exclusivityMarch 2033FDA regulatory exclusivity expiry

CompanyIntercept Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand name	LYNAVOY
Active ingredient	LINERIXIBAT
Strength	40MG
Dosage form	TABLET
Route	ORAL
Modality	Small molecule
FDA approval	March 2026
Marketing status	RX

Listed patents

Patent	Expires	Type
9040518	September 2031	substance, product

Regulatory exclusivity

Code	Expires
ODE-517	March 2033
NCE	March 2031

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the FDA regulatory exclusivity expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from Intercept Pharmaceuticals